Shares in tiny pharmaceutical Prima Biomed surged after a clinical trial showed its breast cancer drug is safe.
A short time ago, the shares were up 22.5% to $0.038.
“This very positive data is a major milestone,” says chief medical officer Dr Frédéric Triebel.
Prima BioMed is a globally active biotechnology company developing immunotherapeutic products.
Business Insider Emails & Alerts
Site highlights each day to your inbox.